How blocking androgen receptors affects T cell function in cancer patients
Effects of androgen receptor antagonists on human T cell function
This study is looking at how certain prostate cancer treatments affect the immune system, specifically T cells, to find ways to make cancer therapies work better, especially for patients with prostate and breast cancers.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Portland NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-10515248 on NIH RePORTER |
What this research studies
This research investigates the impact of androgen receptor antagonists, commonly used in prostate cancer treatment, on the function of human T cells. By understanding how these therapies influence immune responses, the study aims to uncover mechanisms that could enhance the effectiveness of cancer treatments, particularly immunotherapy. The research will involve analyzing T cell behavior in patients undergoing androgen deprivation therapy, which is crucial for improving treatment strategies for prostate and breast cancers. The findings could lead to better combination therapies that leverage the immune system to fight cancer more effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research include men with prostate cancer and women with androgen receptor positive breast cancer who are receiving or have received androgen deprivation therapy.
Not a fit: Patients who do not have prostate cancer or androgen receptor positive breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatment options that enhance immune responses in patients undergoing androgen deprivation therapy.
How similar studies have performed: Previous research has shown promising results in combining immunotherapy with androgen deprivation therapy, indicating that this approach may lead to significant advancements in cancer treatment.
Where this research is happening
Portland, United States
- University of Portland — Portland, United States (Active)
Researchers
- Principal investigator: Murray, Susan E — University of Portland
- Study coordinator: Murray, Susan E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.